IN THE SPOTLIGHT

FDA Approves Amivantamab-vmjw for EGFR Exon 20 Insertion–Mutated NSCLC

FDA Approves Amivantamab-vmjw for EGFR Exon 20 Insertion–Mutated NSCLC

Addition of Nivolumab to Chemotherapy in EGFR-Mutant Metastatic NSCLC After Disease Progression on Prior Therapy

Addition of Nivolumab to Chemotherapy in EGFR-Mutant Metastatic NSCLC After Disease Progression on Prior Therapy

Risks of Cardiovascular Disease in Patients Receiving Therapies for Lung Cancer

Risks of Cardiovascular Disease in Patients Receiving Therapies for Lung Cancer

Osimertinib vs Sequential Gefitinib/Osimertinib in Advanced EGFR-Mutant NSCLC

Osimertinib vs Sequential Gefitinib/Osimertinib in Advanced EGFR-Mutant NSCLC

Osimertinib With Chemotherapy for EGFR-Mutated NSCLC

Osimertinib With Chemotherapy for EGFR-Mutated NSCLC

Amivantamab-vmjw in NSCLC With EGFR Exon 20 Insertion Mutations

Amivantamab-vmjw in NSCLC With EGFR Exon 20 Insertion Mutations

Dr Rodriguez on Treating Patients With Lung Cancer Harboring Multiple Actionable Mutations

Dr Rodriguez on Treating Patients With Lung Cancer Harboring Multiple Actionable Mutations

Treating Women With Lung Cancer: Screening, Treatment, and Sexual and Reproductive Health

Treating Women With Lung Cancer: Screening, Treatment, and Sexual and Reproductive Health

FDA Grants BTD to Sunvozertinib in EGFR Exon20+ NSCLC

FDA Grants BTD to Sunvozertinib in EGFR Exon20+ NSCLC

The Rise of ADC Anticancer Drugs: Enhertu Sparks Global Craze and Competition in the Pharmaceutical Industry

The Rise of ADC Anticancer Drugs: Enhertu Sparks Global Craze and Competition in the Pharmaceutical Industry